© 2026 Monument Traders Alliance, LLC
Picture a sharp chest pain that sends you to the ER, then comes back a few months later, and then again after that.
Doctors call it recurrent pericarditis. The thin sac around the heart gets inflamed, and for thousands of patients it keeps flaring up for years.
One company sells a drug approved to treat it, and business is booming. Sales jumped 55% last quarter, and management has raised its full-year forecast twice this year. That puts this one drug close to $1 billion a year.
It’s barely scratched the surface, too. At the end of June, only about 1 in 5 of the roughly 14,000 patients with repeat flare-ups were on it. The company is profitable, with more than $500 million in cash and no debt.
Many traders are still betting against it.
Tech got hit hard this week, but this stock rose while the indexes fell. It’s at an all-time high with a high short float, meaning a big chunk of its shares have been shorted.
It’s been stuck in a squeeze for about two months, and yesterday it finally started to perk up.
Earnings come in early November. We’ve already got three wins on it in Daily Profits Live this week, and in my opinion, this thing is going to break out.
In today’s video, I’ll show you the name, the spot where I like it, and why time decay won’t eat these options the way you’d expect.
One of the wildest short squeezes ever started 18 years ago this month. On October 26, 2008, Porsche revealed it had locked up about 74% of Volkswagen’s voting shares through stock and options, leaving far fewer shares out there than short sellers needed to buy back.
In less than two days, VW shot from about €210 to more than €1,000 a share. For a moment on October 28, it was the most valuable company in the world, ahead of ExxonMobil, and hedge funds that bet against it lost an estimated $30 billion.
